These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7765291)

  • 1. Monoclonal antibodies: clinical and regulatory issues.
    Thorpe R
    Trends Biotechnol; 1993 Feb; 11(2):40-2. PubMed ID: 7765291
    [No Abstract]   [Full Text] [Related]  

  • 2. Difficult decisions.
    Nat Med; 2011 Aug; 17(8):901. PubMed ID: 21818065
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibodies market.
    Reichert J; Pavolu A
    Nat Rev Drug Discov; 2004 May; 3(5):383-4. PubMed ID: 15152631
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal and engineered antibodies for human parenteral clinical use: regulatory considerations.
    Manohar V; Hoffman T
    Trends Biotechnol; 1992 Sep; 10(9):305-9. PubMed ID: 1369087
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproductive toxicity testing of therapeutic biotechnology agents.
    Henck JW; Hilbish KG; Serabian MA; Cavagnaro JA; Hendrickx AG; Agnish ND; Kung AH; Mordenti J
    Teratology; 1996 Mar; 53(3):185-95. PubMed ID: 8761886
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotechnology. Go-ahead for Centocor.
    Gershon D
    Nature; 1991 Sep; 353(6340):101. PubMed ID: 1891035
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory agency concerns in the manufacturing and testing of monoclonal antibodies for therapeutic use.
    Baker DA; Harkonen WS
    Targeted Diagn Ther; 1990; 3():75-98. PubMed ID: 2131019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDL's mAb technology finds right timing.
    Fletcher L
    Nat Biotechnol; 2001 May; 19(5):395-6. PubMed ID: 11328982
    [No Abstract]   [Full Text] [Related]  

  • 11. An Open Letter to Health Canada.
    Papp K; Albrecht L; Barber K; Bourcier M; Dion PL; Freiman A; Gooderham M; Guenther L; Gulliver W; Hong CH; Lynde C; Poulin Y; Siddha S; Toole J; Toth D; Vender R; Wasel N; Wiseman M
    J Cutan Med Surg; 2017; 21(3):195-196. PubMed ID: 28903599
    [No Abstract]   [Full Text] [Related]  

  • 12. Genentech and IDEC await approval of lymphoma Mab.
    Nat Biotechnol; 1997 Apr; 15(4):301. PubMed ID: 9094110
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotechnology drugs create new maze of concerns for hospitals.
    Lumsdon K
    Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRIME time at the EMA.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):226-228. PubMed ID: 28356591
    [No Abstract]   [Full Text] [Related]  

  • 15. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 16. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 17. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing innovation into a registered product: From concept to regulatory approval.
    Rhodes L
    Theriogenology; 2018 May; 112():75-81. PubMed ID: 28716338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):133-8. PubMed ID: 1888492
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy.
    Bogard WC; Dean RT; Deo Y; Fuchs R; Mattis JA; McLean AA; Berger HJ
    Semin Nucl Med; 1989 Jul; 19(3):202-20. PubMed ID: 2669129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.